Blast From the Past: “Pay for Delay” and the Blockbuster Patent Settlement
This article was originally published in RPM Report
Executive Summary
The Supreme Court wades into the competitive impact of so-called pay-for-delay settlements, while AstraZeneca and Actavis agree on the end of Crestor’s exclusivity period. Those developments are important – but not nearly as much as they used to be.
You may also be interested in...
Baycol Withdrawal Gives Boost To Pravachol; Will Crestor NDA Be Affected?
Bristol-Myers Squibb's Pravachol is gaining share in the retail market in the early days following the withdrawal of Bayer's Baycol, prescription tracking data from ArcLight indicate.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.